



PRESS RELEASE

FURTHER EXPANSION FOR QUOTIENT BIORESEARCH IN DRUG DEVELOPMENT SERVICES ACQUISITION OF BIODYNAMICS BUILDS CAPACITY AND SERVICE OFFERING

Newmarket, United Kingdom, February 6, 2008 - Quotient BioResearch Limited ("Quotient BioResearch"), the leading European provider of analytical and safety evaluation services and products for bioscience and sport, is pleased to announce that it has acquired BioDynamics Research Limited ("BioDynamics").

Founded over 15 years ago, BioDynamics is a leading, specialist provider of metabolism, bioanalytical and radiochemistry services to the world-wide pharmaceutical and biotechnology industries. BioDynamics has annual revenues of over £7.0 million and 100 employees.

BioDynamics represents the fourth acquisition to date for Quotient BioResearch, which was established in early 2007. The enlarged group will have revenues of over £35 million and employ approximately 350 people in the United Kingdom. The Group will continue to operate from its existing sites in Newmarket, Rushden, London and Edinburgh.

Paul Cowan, Chairman and Chief Executive Officer of Quotient BioResearch said, "We are very pleased to have completed the acquisition of BioDynamics. It brings with it a world-wide reputation and complements extremely well the drug development capabilities of our existing businesses in this area, HFL and GR Micro."

"We have experienced considerable growth in demand for the drug development services we offer. The combination with BioDynamics will allow Quotient BioResearch to both increase capacity and extend the range of services it offers for the benefit of its clients. We will be making major investments at both BioDynamics and Quotient BioResearch to further underpin our commitment to meeting the current and future requirements of our clients," Cowan said.

Stephen Lewinton, Managing Director of BioDynamics, said, "The combination of BioDynamics and Quotient BioResearch offers great promise, both for our employees and for our clients. Having established a strong business in the area of drug development services we now look forward to a future as part of a group with the focus of Quotient BioResearch."

BioDynamics represents the third acquisition for Quotient BioResearch in the drug development services sector over the past 12 months. Further acquisitions are anticipated with a view to offering clients a broader, unified range of services. As a consequence of this, the drug development services businesses of Quotient BioResearch will commence trading under the Quotient name from May 2008. The sports testing and research business of Quotient BioResearch will continue to trade as HFL. Alba Bioscience, the diagnostics reagents business of Quotient BioResearch, will continue to trade as Alba Bioscience.

Ulster Bank Limited, a subsidiary of Royal Bank of Scotland, provided the debt finance for the acquisition. Ernst & Young, Belfast acted as financial adviser and Mishcon de Reya as legal adviser to Quotient BioResearch.

- ENDS -

Notes for editors follow:

Contacts:

Quotient BioResearch Paul Cowan, Chairman, and Chief Executive Officer
+44 (0)1638 720 500

Gordon Cameron, Chief Financial Officer
+44 (0)1638 720 500

BioDynamics Research Limited Stephen Lewinton, Managing Director
+44 (0) 1638 720 500

Contacts for the media: Rachel Holdsworth/Helen Goldrein, PR consultants Holdsworth Associates
+44 (0)1954 202789
Rachel@holdsworth-associates.co.uk

About Quotient BioResearch Limited - www.quotientbioresearch.co.uk

Quotient BioResearch was founded in 2007 by Paul Cowan, the former Chief Financial Officer of Inveresk Research Group, Inc. Cowan left Inveresk Research in 2004 following its sale to Charles River Laboratories for approximately \$1.5 billion.

The principal investors in Quotient BioResearch are Paul Cowan, property companies Helical Bar plc and Dencora and the Group's management and employees.

Quotient BioResearch is focused on building a global group providing high value-added analytical and safety evaluation services and products for the bioscience industries, including sport for which it has (through HFL) internationally respected expertise.

The strategic plan of Quotient BioResearch is to grow through acquisition, investment and recruitment. In 2007, Quotient BioResearch acquired:

- HFL, a leading European provider of drug surveillance testing services for sport and bioanalytical and biomarker testing services to the pharmaceutical and biotechnology sectors;
- Alba Bioscience, a leading provider of diagnostic reagents, principally for blood typing; and
- GR Micro, a leading provider of microbiology and molecular biology services to the global pharmaceutical and biotechnology sectors.

In February 2008, Quotient acquired BioDynamics.

BioDynamics

BioDynamics is a specialist drug development services business focused on the provision of metabolism, bioanalytical and radio chemistry services. This combination allows BioDynamics to offer a wide range of specialist services spanning early drug discovery through to product registration.